Citation: Han Yuan, Fengcai Zhang, Hongzhe Huang, Jiafei Wu, Yi Yang, Wanyi Huang, Dongjing Yang, Zhuoming Li, Zhe Li, Ling Huang, Yi-You Huang, Hai-Bin Luo, Lei Guo. Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy[J]. Chinese Chemical Letters, ;2025, 36(4): 109965. doi: 10.1016/j.cclet.2024.109965 shu

Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy

Han Yuan ^{a, 1} ,
Fengcai Zhang ^{a, 1} ,
Hongzhe Huang ^{a, 1} ,
Jiafei Wu ^a ,
Yi Yang ^a ,
Wanyi Huang ^a ,
Dongjing Yang ^a ,
Zhuoming Li ^a ,
Zhe Li ^a ,
Ling Huang ^b ,
Yi-You Huang ^{b, *,} ,
Hai-Bin Luo ^{b, *,} ,
Lei Guo ^{a, *,}

a.
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
b.
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China

hyyou@hainanu.edu.cn

hbluo@hainanu.edu.cn

guolei7@mail.sysu.edu.cn

Received Date: 3 March 2024
Revised Date: 29 April 2024
Accepted Date: 2 May 2024
Available Online: 3 May 2024

Figures(4)

Recently, MP-10, a previous drug candidate with potent inhibition of phosphodiesterase 10A (PDE10A) in clinical phase II trials for schizophrenia or Alzheimer's disease, has shown significant potential in preventing and treating cardiovascular diseases. However, its poor metabolic stability and high permeability across the blood-brain barrier (BBB) make it unsuitable for preventing and treating peripheral cardiovascular diseases. Herein, the hit-to-lead optimization was performed to discover novel 3-trifluoromethyl-substituted pyrazole derivatives as potent and selective PDE10A inhibitors. The structure-activity relationships, biological characterization, molecular mechanism, and drug-like evaluation were discussed to identify compound C7 which showed potent inhibition against PDE10A (half maximal inhibitory concentration, IC₅₀ = 11.9 nmol/L), more than 840-fold selectivity over other PDE subtypes, enhanced liver microsomes stability (T_1/₂ = 239 min) compared to MP-10 and low BBB permeability. Importantly, oral pretreatment with C7·3HCl at a dose of 5.0 mg/kg significantly attenuated the pathological and functional changes induced by isoprenaline (ISO)-induced pathological cardiac hypertrophy in mice, particularly suppressing increase of cardiac weight, atrial natriuretic peptide (ANP) and β-myosin heavy chain (β-MHC) hypertrophic markers along with cardiac fibrosis. These findings further support that targeting PDE10A provides an innovative therapeutic approach for preventing and treating cardiac diseases.
- Phosphodiesterase,
- Inhibitor,
- Drug design,
- Isoprenaline,
- Cardiac hypertrophy
1. [1]
  A. Groenewegen, F.H. Rutten, A. Mosterd, A.W. Hoes, Eur. J. Heart Fail. 22 (2020) 1342–1356. doi: 10.1002/ejhf.1858
2. [2]
  R. Kamel, J. Leroy, G. Vandecasteele, R. Fischmeister, Nat. Rev. Cardiol. 20 (2023) 90–108. doi: 10.1038/s41569-022-00756-z
3. [3]
  C. Jansen, A.J. Kooistra, G.K. Kanev, et al., J. Med. Chem. 59 (2016) 7029–7065. doi: 10.1021/acs.jmedchem.5b01813
4. [4]
  S. Chen, C. Yan, Expert Opin. Drug Discov. 16 (2021) 183–196. doi: 10.1080/17460441.2020.1821643
5. [5]
  N.F. Nadur, L.L. de Azevedo, L. Caruso, et al., Eur. J. Med. Chem. 212 (2021) 113123. doi: 10.1016/j.ejmech.2020.113123
6. [6]
  M.E.J. Preedy, Cardiovasc. Drugs Ther. 34 (2020) 401–417. doi: 10.1007/s10557-020-06959-1
7. [7]
  Q. Fu, Y. Wang, C. Yan, Y.K. Xiang, Physiol. Rev. 104 (2023) 765–834.
8. [8]
  P. Bobin, M. Belacel-Ouari, I. Bedioune, et al., Arch. Cardiovasc. Dis. 109 (2016) 431–443. doi: 10.1016/j.acvd.2016.02.004
9. [9]
  K. Fujishige, J. Kotera, H. Michibata et al., J. Biol. Chem. 274 (1999) 18438–18445. doi: 10.1074/jbc.274.26.18438
10. [10]
  S. Chen, Y. Zhang, J.K. Lighthouse, et al., Circulation 141 (2020) 217–233. doi: 10.1161/circulationaha.119.042178
11. [11]
  L. Luo, Y. Cai, Y. Zhang, et al., Cardiovasc. Res. 118 (2022) 2703–2717. doi: 10.1093/cvr/cvab304
12. [12]
  X. Tian, C. Vroom, H.A. Ghofrani, et al., PLoS ONE 6 (2011) e18136. doi: 10.1371/journal.pone.0018136
13. [13]
  Y. Yang, S. Zhang, Q. Zhou, et al., Acta Pharm. Sin. B 10 (2020) 2339–2347. doi: 10.1016/j.apsb.2020.04.003
14. [14]
  H.S. Amin, P.K. Parikh, M.D. Ghate, Eur. J. Med. Chem. 214 (2021) 113155. doi: 10.1016/j.ejmech.2021.113155
15. [15]
  H. Geerts, A. Spiros, P. Roberts, Expert Rev. Neurother. 17 (2017) 553–560. doi: 10.1080/14737175.2017.1268531
16. [16]
  W. Hamaguchi, N. Masuda, S. Miyamoto, et al., Bioorg. Med. Chem. 23 (2015) 297–313. doi: 10.1016/j.bmc.2014.11.039
17. [17]
  P.R. Verhoest, D.S. Chapin, M. Corman, et al., J. Med. Chem. 52 (2009) 5188–5196. doi: 10.1021/jm900521k
18. [18]
  W. Hamaguchi, N. Masuda, K. Samizu, et al., Chem. Pharm. Bull. 62 (2014) 1200–1213. doi: 10.1248/cpb.c14-00509
19. [19]
  A. Garrido, A. Lepailleur, S.M. Mignani, P. Dallemagne, C. Rochais, Eur. J. Med. Chem. 195 (2020) 112290. doi: 10.1016/j.ejmech.2020.112290
20. [20]
  T.A. Chappie, C.J. Helal, X. Hou, J. Med. Chem. 55 (2012) 7299–7331. doi: 10.1021/jm3004976
21. [21]
  L. Di, E.H. Kerns, K. Fan, O.J. McConnell, G.T. Carter, Eur. J. Med. Chem. 38 (2003) 223–232. doi: 10.1016/S0223-5234(03)00012-6
1. [1]
  Sajid Hussain , Omer M.A. Dagah , Essam A.M.S Obaid , Peng Jin , Ovas Ahmed Dar , Muhammd Irfan , Yiming Qi , Qinghua Wu , Ming Jin , Tengli Zhang , Lei Luo . Chitosan as oral absorption enhancer and inhibitor: A comprehensive review. Chinese Chemical Letters, 2026, 37(1): 111273-. doi: 10.1016/j.cclet.2025.111273
2. [2]
  Zhexin Chen , Yuqing Shi , Fang Zhong , Kai Zhang , Furong Zhang , Shenghong Xie , Zhongbin Cheng , Qian Zhou , Yi-You Huang , Hai-Bin Luo . Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects. Chinese Chemical Letters, 2025, 36(4): 109956-. doi: 10.1016/j.cclet.2024.109956
3. [3]
  Bairu Meng , Zongji Zhuo , Han Yu , Sining Tao , Zixuan Chen , Erik De Clercq , Christophe Pannecouque , Dongwei Kang , Peng Zhan , Xinyong Liu . Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3-d]pyrimidine derivatives as novel HIV-1 NNRTIs. Chinese Chemical Letters, 2024, 35(6): 108827-. doi: 10.1016/j.cclet.2023.108827
4. [4]
  Xue-Wen Wu , Bin-Bao Wang , Yu Qin , Yong-Xiang Huang , Muhammad Aurang Zeb , Bin Cheng , Xiao-Li Li , Chang-Bo Zheng , Wei-Lie Xiao . Diterpenoids with unexpected 5/6/6-fused ring system and its dimer from Strophioblachia glandulosa. Chinese Chemical Letters, 2025, 36(8): 110584-. doi: 10.1016/j.cclet.2024.110584
5. [5]
  Yi-Ru Bai , Qing-Chuan Duan , Dong-Jie Seng , Ying Xu , Hong-Bo Ren , Jie Zhang , Dan-Dan Shen , Li Yang , Hong-Min Liu , Shuo Yuan . A comprehensive review of small molecule drugs approved by the FDA in 2024: Advance and prospect. Chinese Chemical Letters, 2025, 36(10): 111025-. doi: 10.1016/j.cclet.2025.111025
6. [6]
  Chunyu Yan , Qinglong Qiao , Wei Zhou , Xuelian Zhou , Yonghui Chen , Lu Miao , Zhaochao Xu . FRET-based in vitro assay for rapid detecting of SARS-CoV-2 entry inhibitors. Chinese Chemical Letters, 2025, 36(5): 110258-. doi: 10.1016/j.cclet.2024.110258
7. [7]
  Deyan Wu , Qingjiang Ma , Yanquan Chen , Guofeng Yang , Fengcai Zhang , Meiyan Jiang , Xue Wang , Xingfu Liu , Qian Zhou , Yi-You Huang , Zhe Li , Hai-Bin Luo . Plasma metabolites-based drug design: Discovery of novel and highly selective phosphodiesterase 5 inhibitors. Chinese Chemical Letters, 2026, 37(5): 111236-. doi: 10.1016/j.cclet.2025.111236
8. [8]
  Anqi Shi , Jiahao Xiang , Qingyun Zhang , Minghui Tan , Wen Xiao , Yang Yang , Lin Zhao , Jian Liu , An Pan , Junwei Wang , Lihong Hu . Discovery of a novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. Chinese Chemical Letters, 2026, 37(8): 111786-. doi: 10.1016/j.cclet.2025.111786
9. [9]
  Jiawei Zhu , Yucheng Xiong , Xiaoxue Bai , Chenlong Xie , Baichen Xiong , Yao Chen , Haopeng Sun . Small molecule-drug conjugates: Mechanistic insights and strategic design for enhanced cancer therapy. Chinese Chemical Letters, 2025, 36(10): 110799-. doi: 10.1016/j.cclet.2024.110799
10. [10]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
11. [11]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
12. [12]
  Chao Chen , Wenwen Yu , Guangen Huang , Xuelian Ren , Xiangli Chen , Yixin Li , Shenggui Liang , Mengmeng Xu , Mingyue Zheng , Yaxi Yang , He Huang , Wei Tang , Bing Zhou . Asymmetric macrocyclization enabled by Rh(Ⅲ)-catalyzed CH activation: Enantioenriched macrocyclic inhibitor of Zika virus infection. Chinese Chemical Letters, 2024, 35(11): 109574-. doi: 10.1016/j.cclet.2024.109574
13. [13]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
14. [14]
  Chanqi Ye , Jia Zhang , Jie Shen , Ruyin Chen , Qiong Li , Peng Zhao , Dong Chen , Jian Ruan . Attractive Pickering emulsion gel loaded with oxaliplatin and lactate dehydrogenase inhibitor increases the anti-tumor effect in hepatocellular carcinoma. Chinese Chemical Letters, 2025, 36(7): 110519-. doi: 10.1016/j.cclet.2024.110519
15. [15]
  Wenchao Chen , Xiaoting Niu , Xinyu Liang , Guanghao Zhu , Xue Zhang , Qing Gong , Cen Xie , Guangbo Ge , Ping Wang , Yuqi He . Rationally engineered a universal far-red fluorogenic substrate of bile salt hydrolase for functional imaging and inhibitor screening. Chinese Chemical Letters, 2026, 37(4): 111320-. doi: 10.1016/j.cclet.2025.111320
16. [16]
  Yin-Xiang Zhang , Christophe Pannecouque , Erik De Clercq , Enzo Tramontano , Angela Corona , Laura Dettori , Phuong-Thao Tran , Xu-Dong Li , Shuo Su , Shuai Wang , Fen-Er Chen . Discovery of novel and potent non-nucleoside reverse transcriptase inhibitors through structure-based drug design for HIV treatment. Chinese Chemical Letters, 2026, 37(8): 112448-. doi: 10.1016/j.cclet.2026.112448
17. [17]
  Jisheng Liu , Junli Chen , Xifeng Zhang , Yin Wu , Xin Qi , Jie Wang , Xiang Gao . Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment. Chinese Chemical Letters, 2024, 35(9): 109779-. doi: 10.1016/j.cclet.2024.109779
18. [18]
  Hui Lei , Yingying Jiang , Jiayu Liu , Weifeng Zhang , Fanbo Meng , Jun Mou , Wenyi Liu , Pengcheng Lei , Rui Xiong , Zan Xu , Hang Zhang , Yanjun Wang , Guo-Bo Li , Lingling Yang , Hua-Li Wang . Structure-activity relationship studies of 3,4-disubstitued indole-2-ketone derivatives identify a potent glutaminyl cyclase inhibitor with antitumor activity against breast cancer. Chinese Chemical Letters, 2026, 37(6): 111511-. doi: 10.1016/j.cclet.2025.111511
19. [19]
  Feng Xu , Ziqi Ning , Donghua Zhang , Chunlong Dai , Qinxue Wen , Fengxia Deng , Bo Lai , Zhiqiang Chen . Mechanism and pathway for the electrocatalytic degradation of an organic phosphine scale inhibitor by a novel Ti/IrO₂-RuO₂(Bi+[Emim]BF₄) electrode. Chinese Chemical Letters, 2026, 37(10): 112435-. doi: 10.1016/j.cclet.2026.112435
20. [20]
  Xueyi Weng , Weiyan Li , Haipeng Tan , Zhiqing Pang , Jinfeng Gao , Shiteng Cai , Jing Chen , Qiaozi Wang , Qiyu Li , Youran Li , Hongbo Yang , Zhengmin Wang , Yiwen Tan , Yuyuan Fu , Chengzhi Han , Zheyong Huang , Yanan Song , Junbo Ge , Juying Qian . Engineered macrophage membrane fusion liposomes carrying siRNA for spatiotemporal regulation of the CCL2/CCR2 axis for cardiac repair. Chinese Chemical Letters, 2026, 37(7): 111666-. doi: 10.1016/j.cclet.2025.111666

Get Citation

PDF

XML

Metrics

PDF Downloads(7)
Abstract views(2368)
HTML views(100)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142